Meanwhile, lapatinib, which clusters in the latter group, is effective for patients with HER2-positive breast cancer and has been shown to synergize with anti-ER therapy (Korkaya et al. 2012; Ithimakin et al. 2013) in a subset of ERBB2-amplified tumors that express ESR1. This evidence concerns the gene ESR1 and breast cancer.